U.S. appeals court invalidates Acorda patents on MS drug
A U.S. appeals court on invalidated Acorda Therapeutics Inc patents covering its multiple sclerosis drug Ampyra, opening the door for generic competition for Acorda's flagship product.
The U.S. Court of Appeals for the Federal Circuit affirmed a lower court ruling that four Acorda patents on Ampyra were invalid because they described obvious ideas. Japanese generic drugmaker Hikma Pharmaceuticals had challenged the validity of the patents.
Acorda's stock dropped more than 22 per cent to $21.40 after the ruling
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd